<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939923</url>
  </required_header>
  <id_info>
    <org_study_id>WVU Protocol #: 1806161309</org_study_id>
    <nct_id>NCT03939923</nct_id>
  </id_info>
  <brief_title>Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery</brief_title>
  <official_title>Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether the use of Sugammadex will reduce time from
      reversal to extubation and improve other post extubation outcomes in Coronary artery bypass
      grafting patients. This study is a prospective, clinical interventional, randomized single
      blinded single-center design. The nurses in the cardiac intensive care unit will be blinded
      to treatment allocation (Group 1 or 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enhanced recovery pathways and early extubation of subjects undergoing cardiac procedures has
      now become mainstay, especially with the advent of minimally invasive procedures .

      To facilitate optimal recovery after extubation; muscle strength is vital to prevent
      reintubation, improved deglutition and quicker transition to lower oxygen requirements, and
      better respiratory and cardiac hemodynamics. It also expedites de-escalation of acuity of
      care. Several studies have shown residual muscle weakness after full reversal with
      neostigmine and glycopyrrolate. Sugammadex is a direct reversal agent and can provide
      superior muscle strength, which optimizes respiratory function thereby preventing
      atelectasis, hypoxia and potentially avoiding reintubation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015 mg/kg up to 1mg maximal dosage).
Group 2 (treatment) will receive reversal with sugammadex 2 mg/kg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>The nurses in the cardiac intensive care unit will be blinded to treatment allocation (Group 1 or 2).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Extubation</measure>
    <time_frame>at 0 minutes of study drug to 3 days after study drug administration</time_frame>
    <description>Time to extubation: West Virginia University Hospitals use an electronic medical record (EMR) to chart &quot;procedure stop.&quot; The definition for &quot;time to extubation&quot; is from the time the investigators chart &quot;procedure stop&quot; to the time of &quot;extubation&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>at 0 mintues to 2 hours after study drug administration</time_frame>
    <description>Heart rate post-reversal prior to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>at 0 mintues to 2 hours after study drug administration</time_frame>
    <description>Blood pressure post-reversal prior to extubation, both systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tidal Volume</measure>
    <time_frame>between 30 minutes to 1 hour after extubation</time_frame>
    <description>Tidal volume post-reversal prior to extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Flow Rate</measure>
    <time_frame>30-60 minutes post-extubation</time_frame>
    <description>Peak flow rate - measured by peak flow meter post-extubation at 30-60 mins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing Capacity</measure>
    <time_frame>30-60 minutes post-extubation</time_frame>
    <description>Swallowing capacity measured by Functional Dysphagia screen administered at 30 - 60 mins post extubation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Oxygen Saturation</measure>
    <time_frame>2 hours post-extubation every 15 minutes</time_frame>
    <description>Oxygen saturation post-extubation for subsequent 2 hours documented every 15 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-extubation Oxygen Requirements</measure>
    <time_frame>2 hours post-extubation</time_frame>
    <description>Post-extubation Oxygen requirements in subsequent 2 hours</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Stay cardiac intensive care unit</measure>
    <time_frame>0 days after study drug to 100 days after study drug</time_frame>
    <description>Length of stay in the cardiac intensive care from onset of reversal drugs</description>
  </other_outcome>
  <other_outcome>
    <measure>Reintubation Incidence</measure>
    <time_frame>24 hours post-extubation</time_frame>
    <description>Reintubation incidence in the first 24 hours post-extubation</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of Postoperative Respiratory Complications</measure>
    <time_frame>0 hours after study drug to 24 hours after study drug</time_frame>
    <description>Postoperative respiratory complication</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurrence of Postoperative Cardiac Complications</measure>
    <time_frame>from 0 hours after study drug to 2 hours after study drug</time_frame>
    <description>Postoperative cardiac complications.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Surgery</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Group One</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 1 (control) will receive reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage) and glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Two</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2: Intubation with rocuronium at 1.0-1.2 mg/kg (vitals maintained within 20% of baseline). Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure to maintain 1-2 twitches on TOF watch monitor reading recorded every 15 minutes. Group 2 (treatment) will receive reversal with Sugammadex (2mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.</description>
    <arm_group_label>Group One</arm_group_label>
    <arm_group_label>Group Two</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)</description>
    <arm_group_label>Group One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)</description>
    <arm_group_label>Group One</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>Reversal with Sugammadex (2mg/kg)</description>
    <arm_group_label>Group Two</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 70 years

          -  American Society of Anesthesiology physical status I-4

          -  Isolated coronary artery bypass graft surgery

          -  Ability to give written informed consent

        Exclusion Criteria:

          -  Any other surgical procedure concomitant to CABG surgery

          -  Known or suspected neuromuscular disease/pre-existing weakness

          -  Creatinine clearance less than 30 ml/min

          -  Bradycardia of less than 40 beats/min

          -  Pregnancy, breastfeeding women

          -  Known or suspected allergy to BRIDION® (sugammadex),neostigmine, or rocuronium

          -  Patients with contraindications towards sugammadex, neostigmine, or rocuronium

          -  Patients included in another trial within the last 30 days

          -  Patients with legal guardians or surrogate decision-making

          -  Female Patients who refuse to use non-hormonal contraceptive method or back-up method
             of contraception (such as condoms and spermicides) for the next 7 days if receiving
             sugammadex.

          -  Patients undergoing emergency surgery

          -  Patient refusal

          -  Patients with ejection fraction &lt;30%

          -  Patients with restrictive and obstructive lung disease

          -  Patients with obstructive sleep apnea

          -  Patients with Body Mass Index greater than 40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew Ellison, MD</last_name>
    <phone>304-598-4929</phone>
    <email>mellison@wvumedicine.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Connie Tennant, RN, CCRP</last_name>
    <phone>304-598-6193</phone>
    <email>cstennant@wvumedicine.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>WVU Medicine</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Ellison, MD</last_name>
      <phone>304-598-4929</phone>
      <email>mellison@wvumedicine.org</email>
    </contact>
    <contact_backup>
      <last_name>Connie Tennant, RN, CCRP</last_name>
      <phone>304-598-6193</phone>
      <email>cstennant@wvumedicine.org</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Ellison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavithra Ranganathan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Grose, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heather Hayanga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff Puette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Sloyer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Cook, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vinay Badhwar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Muhammad Salman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold Roberts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lawrence Wei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Badhwar V, Esper S, Brooks M, Mulukutla S, Hardison R, Mallios D, Chu D, Wei L, Subramaniam K. Extubating in the operating room after adult cardiac surgery safely improves outcomes and lowers costs. J Thorac Cardiovasc Surg. 2014 Dec;148(6):3101-9.e1. doi: 10.1016/j.jtcvs.2014.07.037. Epub 2014 Jul 31.</citation>
    <PMID>25173117</PMID>
  </reference>
  <reference>
    <citation>Subramaniam K, DeAndrade DS, Mandell DR, Althouse AD, Manmohan R, Esper SA, Varga JM, Badhwar V. Predictors of operating room extubation in adult cardiac surgery. J Thorac Cardiovasc Surg. 2017 Nov;154(5):1656-1665.e2. doi: 10.1016/j.jtcvs.2017.05.107. Epub 2017 Jun 13.</citation>
    <PMID>28711332</PMID>
  </reference>
  <reference>
    <citation>Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, Parikh KN, Patel SS, Patel A. Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications. Anesthesiology. 2015 Dec;123(6):1322-36. doi: 10.1097/ALN.0000000000000865. Erratum in: Anesthesiology. 2016 May;124(5):1201.</citation>
    <PMID>26448469</PMID>
  </reference>
  <reference>
    <citation>Murphy GS, Kopman AF. &quot;To Reverse or Not To Reverse?&quot;: The Answer Is Clear! Anesthesiology. 2016 Oct;125(4):611-4. doi: 10.1097/ALN.0000000000001280.</citation>
    <PMID>27496655</PMID>
  </reference>
  <reference>
    <citation>Herbstreit F, Zigrahn D, Ochterbeck C, Peters J, Eikermann M. Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology. 2010 Dec;113(6):1280-8. doi: 10.1097/ALN.0b013e3181f70f3d.</citation>
    <PMID>20980910</PMID>
  </reference>
  <reference>
    <citation>Boon M, Martini C, Broens S, van Rijnsoever E, van der Zwan T, Aarts L, Dahan A. Improved postoperative oxygenation after antagonism of moderate neuromuscular block with sugammadex versus neostigmine after extubation in 'blinded' conditions. Br J Anaesth. 2016 Sep;117(3):410-1. doi: 10.1093/bja/aew246.</citation>
    <PMID>27543551</PMID>
  </reference>
  <reference>
    <citation>Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. Anesthesiology. 2013 Jul;119(1):36-42. doi: 10.1097/ALN.0b013e318297ce95.</citation>
    <PMID>23665915</PMID>
  </reference>
  <reference>
    <citation>Paton F, Paulden M, Chambers D, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth. 2010 Nov;105(5):558-67. doi: 10.1093/bja/aeq269. Epub 2010 Oct 8. Review.</citation>
    <PMID>20935005</PMID>
  </reference>
  <reference>
    <citation>Park ES, Lim BG, Lee WJ, Lee IO. Sugammadex facilitates early recovery after surgery even in the absence of neuromuscular monitoring in patients undergoing laryngeal microsurgery: a single-center retrospective study. BMC Anesthesiol. 2016 Aug 2;16(1):48. doi: 10.1186/s12871-016-0221-2.</citation>
    <PMID>27484887</PMID>
  </reference>
  <reference>
    <citation>Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Craig D, Hunter J, Wilson J, Sculpher M, Woolacott N. Sugammadex for the reversal of muscle relaxation in general anaesthesia: a systematic review and economic assessment. Health Technol Assess. 2010 Jul;14(39):1-211. doi: 10.3310/hta14390. Review.</citation>
    <PMID>20688009</PMID>
  </reference>
  <reference>
    <citation>Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Hunter JM, Sculpher M, Woolacott N. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth. 2010 Nov;105(5):568-75. doi: 10.1093/bja/aeq270. Epub 2010 Oct 11. Review.</citation>
    <PMID>20937718</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Matthew Ellison</investigator_full_name>
    <investigator_title>Co-Director Cardiovascular Anesthesiology, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Bypass Grafting Surgery</keyword>
  <keyword>Sugammadex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

